DSS Inc (DSS)

[Patentinvestor]

From the DSS S-3 -

USE OF PROCEEDS

Except as otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of the securities offered by us in this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, and the repayment, refinancing, redemption or repurchase of future indebtedness or capital stock.

Clinical trial expenditures? Interesting
Regulatory Affairs Expenditures? Can you say , "Lobbying"


I'm excited. As JJ said, once this is approved by the SEC, DSS can sell the stock after a major announcement when the stock is higher.

They aren't selling now since they are not approved yet and I think the stock price is way too low for them to fund. This document is a pre-curser to something on the horizon. They are gearing up for an event IMO. They want to be ready to cash in on something and they need to have the paperwork done and approved so they can jump in when it's time.